The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Sir, on the margin question. If I were to adjust the FX impact, it seems like we -- there hasn't been any spend on promotion or marketing despite
us launching Ilumya and XELPROS in the quarter. Whereas, I think you indicated even in the last call, even in this call, we should expect marketing
and launch expenses. Is there some postponement of expense? Or how does it work? I mean, do we see these expenses in the launch quarter
before the launch quarter?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Okay. Understood. That would be more related to the product strategy other than new launches?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: But even in case of Cequa, sir, our field force is already built out, right? So again that would be more variable cost associated with the launch.
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Understood, understood. And sir, my second question is on emerging market. That has seen quite a strong improvement. Any specific reason for
the -- is there any one-off tender, et cetera? I know you've called out a next couple of markets, but is this revenue momentum that we've seen in
the quarter sustainable?
without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.
FEBRUARY 12, 2019 / 1:00PM, SUNPHARMA.NSE - Q3 2019 Sun Pharmaceutical Industries Ltd Earnings Call
Kalyanasundaram Subramanian - Sun Pharmaceutical Industries Limited - CEO of India Business and Emerging Markets & Whole-Time Director
No. There is no one-offs in the numbers. Like I mentioned, few of the markets where our performance has been good is supported by ongoing,
underlying demand for the products.
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Sorry, what was the second thing you said? Certain what kind of expenses you will get?
|
